Notice of annual general meeting in Swedish Orphan Biovitrum AB (publ)
The shareholders in Swedish Orphan Biovitrum AB (publ), Reg. No. 556038-9321, are hereby summoned to the annual general…
The shareholders in Swedish Orphan Biovitrum AB (publ), Reg. No. 556038-9321, are hereby summoned to the annual general…
Swedish Orphan Biovitrum AB's (publ) (Sobi(TM)) Chairman of the Board, Bo Jesper Hansen, MD, PhD, has informed the Sobi…
Despite the currency crisis and a difficult economic environment, the Galenica Group contin-ued to grow in 2011 and gene…
Takeda Pharmaceutical Company Limited ("Takeda", TSE: 4502) announced it has completed its acquisition of Nycomed A/S ("…
Galenica has been strongly affected by the significant drop of both dollar and euro. While the Group generates around tw…
Once-a-day tablet Daxas® (roflumilast) is a first-in-class treatment under development targeting inflammation, the under…
Nycomed today announced that the European Commission has granted marketing authorisation for Instanyl®, its first-in-cla…
. - New drug application filed for United States - Treatment aimed at patients with symptomatic Chronic Obstructive Pu…
Nycomed received marketing authorisation from the European Commission for five applications: PANTOZOL Control®, PANTOLOC…
. - Adjusted EBITDA increased 1.0% to €307.0m (Q1/08: €304.0m) - Total net turnover increased 1.2% to €839.9m (Q1/08:…